Stage III non-small-cell lung cancer (NSCLC) presents a major therapeutic problem for the radiation oncologist who treats patients outside of clinical trials. It is a heterogeneous disease with great variation of the clinical extent, and the optimal therapeutic decision must be based on various parameters: the most important unfavorable characteristics are represented by a low Karnofsky performance status, weight loss > 5%, locally too advanced disease (e.g. T4, positive pleural effusion), intensive symptomatology, and distant metastases. The presence of these factors advocates the use of short hypofractionated radiotherapy (RT) schemes of one or two fractions (e.g., 1 × 10 Gy, 2 × 8.5 Gy), which results in fast and effective palliation. Radical treatment must be given to patients without the above-mentioned unfavorable characteristics. Results from randomized clinical trials support the use of high RT doses, preferably hyperfractionated/ accelerated. The CHART schedule could be used in case of squamous-cell histology. Elderly patients could be treated by the standard scheme of 30 × 2 Gy (or equivalent). Chemotherapy reduces the risk of (other than brain) distant metastases and improves the median survival time, especially for patients with non-squamous-cell NSCLC. Platinum-based chemotherapy is usually administered in conjunction with RT as inductive and/or concurrent. Patients of stage IV are probably candidates for chemotherapy in case of good performance status and for a short-term radiotherapy if local symptoms are predominant.

This content is only available via PDF.
© 2001 S. Karger GmbH, Freiburg
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.